Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Intellia Therapeutics Inc (38I.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
39.54-0.24 (-0.62%)
At close: 09:00PM CET
Advertisement
Full screen
Loading interactive chart...
  • Zacks

    4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

    Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.

  • TheStreet.com

    Does Intellia Therapeutics Stock Have Good Genes?

    CRISPR editing firm Intellia Therapeutics was rated a new fundamental "overweight" (buy) by a sell-side firm Wednesday with a $67 price target. The On-Balance-Volume (OBV) line has been weak with a low just made in January. The weekly OBV line has struggled the past 18 months or so but may have made a low in January.

  • InvestorPlace

    7 CRISPR Stocks With the Best Long-Term Potential

    CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks

Advertisement
Advertisement